High-Risk IgVH-Unmutated Chronic Lymphocytic Leukemia
High-Risk IgVH-Unmutated Chronic Lymphocytic Leukemia
Case:A 62-YearOld Male WithIgVH-Unmutated CLL
- A 62-year-old male presented to PCP with complaints of extreme fatigue and night sweats
- PE: Enlarged mobile lymph nodes bilaterally (~1.5 cm), no palpable spleen or liver
- Laboratory findings:
- WBC; 100 X 109/L
- Lymphocytes; 82 X 109/L
- Hb; 11.2 g/dL
- Platelets; 190 X 109/L
- ANC; 1,950/mm3
- LDH 150 U/L
- Cytogenetic; del(11q),IgVH-unmutated
- β2M, 2.9 mg/L
- Referred to community oncology who diagnosed patient with chronic lymphocytic leukemia
- Patient was started on ibrutinib + rituximab (IR)
- Rai Stage I
Considering the Durability of Zanubrutinib in Relapsed/Refractory CLL
April 11th 2024During a Case-Based Roundtable® event, Marc S. Hoffmann, MD, discussed his viewpoints on the use of Bruton tyrosine kinase inhibitors for patients with relapsed/refractory chronic lymphocytic leukemia and the efficacy behind zanubrutinib in the second article of a 2-part series.
Read More
Lachowiez Considers the Use of Tagraxofusp in BPDCN as Bridge to SCT With Peers
March 21st 2024During a Targeted Oncology™ Case-Based Roundtable™ event, Curtis Lachowiez, MD, discussed targeted therapy for blastic plasmacytoid dendritic cell neoplasm and its role in patients who could receive allogeneic stem cell transplant.
Read More
